Jasper Therapeutics

Notes

Jasper Therapeutics is a clinical-stage biotechnology company developing antibody-based conditioning regimens for stem cell transplants. The company's approach aims to replace toxic chemotherapy and radiation conditioning with targeted antibodies that clear the stem cell niche, potentially making transplants safer and more accessible.

Traditional stem cell transplant conditioning using chemotherapy and radiation causes significant toxicity and limits who can receive transplants. Jasper's lead program JSP191 (anti-CD117 antibody) is designed to selectively deplete stem cells without broader tissue damage.

Jasper went public on NASDAQ (ticker: JSPR) in 2021 and is advancing JSP191 through clinical trials for various indications including severe combined immunodeficiency (SCID) and other conditions requiring stem cell transplant.

Team

• Ronald Martell - CEO
  • LinkedIn: linkedin.com/in/ronaldmartell
• Scientific founders include pioneers in stem cell transplant conditioning

Additional Research Findings

• Founded in 2019, headquartered in Redwood City, California
• Public company on NASDAQ (ticker: JSPR) since 2021
• Portfolio company of Abingworth (pre-IPO)
• Lead program JSP191 (anti-CD117 antibody)
• Antibody-based transplant conditioning
• Replacing chemotherapy/radiation conditioning
• Clinical trials in SCID and other conditions
• Making stem cell transplants safer

Sources

• Jasper Therapeutics Website
• NASDAQ Company Page
• LinkedIn Company Page
• ClinicalTrials.gov